Direct Rx Recalls Lidocaine Ointment Over Subpotency Concerns
Direct Rx is recalling 493 jars of Lidocaine Ointment USP, 5.0% because the medication is subpotent.
Direct Rx is recalling 493 jars of Lidocaine Ointment USP, 5.0% packaged in 50g jars. The prescription drug was distributed nationwide within the United States.
The recall was initiated because the drug was determined to be subpotent. A subpotent drug may fail to deliver the expected pain relief or therapeutic effect.
The ointment was packaged and distributed by Direct Rx, based in Dawsonville, Georgia. The U.S. Food and Drug Administration (FDA) is overseeing this Class II recall.
What to do
- Stop using the recalled Lidocaine Ointment USP, 5.0% immediately.
- Contact Direct Rx or your healthcare provider to discuss a replacement or alternative treatment options.
- Report any health issues or side effects related to the product to the FDA or your physician.
At a glance
| Agency | U.S. Food and Drug Administration (FDA) |
|---|---|
| Recall number | D-0107-2027 |
| Date | 2026-11-04 |
| Company | Direct Rx, Dawsonville, GA |
| Severity | Class II |
| Quantity | 493 jars |
| Where sold | Nationwide within the United States |
| Lot codes / identifiers | LOT#: 03AP2511, 30AP2518, 18JU2519, 18JU2520, Exp. Date 04/30/2027. |
Source: official FDA notice. This summary was written by 365 News from the official notice. Details can change; check the notice before acting.